"In the future, studies should be open to all comers so you get more realistic outcomes based on all patients, not just a subset," Kelly said. From that basis, men taking hormone therapy should be concerned about the risk of cardiovascular problems, he said.
Men taking hormone therapy need to be monitored for potential cardiovascular problems, especially men with a history of heart disease or stroke, Kelly added. For some patients, like men who will not die from their prostate cancer, the risk of hormone therapy may be greater than the benefit, he said.
"You have to understand the risk-benefit ratio in each population. You can't just apply it across the board to all patients," Kelly said.
For more on prostate cancer, visit the U.S. National Cancer Institute.
SOURCES: Paul L. Nguyen, M.D., director, prostate brachytherapy, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston; William K. Kelly, D.O., professor of medical oncology and urology, Thomas Jefferson University, Kimmel Cancer Center, Philadelphia; Dec. 7, 2011, Journal of the American Medical Association
All rights reserved